Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Titel:
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Auteur:
Miles, David Cameron, David Bondarenko, Igor Manzyuk, Lyudmila Alcedo, Juan Carlos Lopez, Roberto Ivan Im, Seock-Ah Canon, Jean-Luc Shparyk, Yaroslav Yardley, Denise A. Masuda, Norikazu Ro, Jungsil Denduluri, Neelima Hubeaux, Stanislas Quah, Cheng Bais, Carlos O'Shaughnessy, Joyce